Torrent Pharmaceuticals has signed an agreement to acquire brands Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin) from Boehringer Ingelheim International GmbH (BI).

The acquisition is expected to be completed in March 2025. Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India.

Empagliflozin is a novel sodium-glucose co-transporter-2 (SGLT-2) inhibitor that is indicated for glycemic control in adults with type 2 diabetes mellitus; The market for SGLT-2 inhibitors is valued at INR 3,235 Crores and the SGLT-2 inhibitors are growing faster than the diabetes market at 25 percent CAGR.

As per the International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2024 data, the Indian diabetes medications market is valued at INR 19,912 crore, growing at 7.7 percent CAGR over the last 4 years.

Commenting on the agreement, Aman Mehta, Director, Torrent, said, “As we continue to strengthen our diabetes care portfolio, we will ensure continued access to the treatment for patients whilst building on our presence in the Oral Anti Diabetic market.”

Torrent Pharma, with an annual revenue of more than INR 10,700 crores, is the flagship company of the Torrent Group, with group revenue of more than ~ INR 41,000 crores.

It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastrointestinal (GI), Central Nervous System (CNS), and Vitamins Minerals Nutritionals (VMN) and Cosmo Dermatology.